Abstract: The type III restriction enzyme EcoP15I is used to isolate from cDNA of an expressed gene a tag comprising more than 25 nucleotides and capable of identifying the expressed gene, wherein the 3? end of the tag is defined by a cleavage site of the type III restriction enzyme and the 5? end of the tag is defined by the cleavage site of another restriction enzyme that is closest to the 3? end of the cDNA of the expressed gene. The tag of the invention allows accurate quantitative gene expression analysis and rapid gene expression profiling in any organism for which no expressed sequence tag (EST) database is available.

Abstract: The present invention relates to the use of a substance or composition comprising one or more proteasome inhibitors for the manufacture of a medicament for the treatment of an individual infected with a virus selected from the group comprising varicella zoster virus, human cytomegalovirus, human herpesvirus 6 and 7 and Epstein-Barr virus and Karposi's sarcoma herpesvirus. The invention further relates to methods of treatment of individuals infected with a virus selected from the group comprising varicella zoster virus, human cytomegalovirus, human herpesvirus 6 and 7 and Epstein-Barr virus and Karposi's sarcoma herpesvirus.

Abstract: A restriction endonuclease having one DNA binding site is proposed, synthesized from a restriction endonuclease that has one C-terminal domain and one N-terminal domain and two DNA binding sites, by proteolytic cleavage into the two domains or by cloning the gene segment that codes for the domains and expression of the domains and selection of the endonucleolytic domains having one DNA binding site. In addition, a method of synthesis of the restriction endonuclease and its use are claimed.

Abstract: The present invention relates to the use of a substance or composition comprising one or more proteasome inhibitors for the manufacture of a medicament for the treatment of an individual infected with a virus selected from the group comprising varicella zoster virus, human cytomegalovirus, human herpesvirus 6 and 7 and Epstein-Barr virus and Karposi's sarcoma herpesvirus. The invention further relates to methods of treatment of individuals infected with a virus selected from the group comprising varicella zoster virus, human cytomegalovirus, human herpesvirus 6 and 7 and Epstein-Barr virus and Karposi's sarcoma herpesvirus.